{
    "Trade/Device Name(s)": [
        "BD Phoenix\u2122M Automated Microbiology System - Cefazolin 0.5-32 \u03bcg/mL EPY",
        "BD Phoenix\u2122 Automated Microbiology System Cefazolin (0.5-32 \u03bcg/mL)"
    ],
    "Submitter Information": "Becton, Dickinson and Company",
    "510(k) Number": "K063811",
    "Predicate Device Reference 510(k) Number(s)": [
        "N50510",
        "K020321",
        "K020323",
        "K020322",
        "K061867"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LON"
    ],
    "Summary Letter Date": "December 20, 2006",
    "Summary Letter Received Date": "December 20, 2006",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.1645"
    ],
    "Regulation Name(s)": [
        "Fully Automated Short-Term Incubation Cycle Antimicrobial Susceptibility Devices"
    ],
    "Analyte Class(es)": [
        "microbiology"
    ],
    "Analyte(s)": [
        "Cefazolin"
    ],
    "Specimen Type(s)": [
        "Isolates from pure culture of Gram-negative aerobic and facultative anaerobic bacteria",
        "Gram-positive bacteria isolates from pure culture"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "BD Phoenix instrument"
    ],
    "Method(s)/Technology(ies)": [
        "Broth based microdilution",
        "Redox indicator for detection of growth",
        "Automated incubation and turbidity measurement"
    ],
    "Methodologies": [
        "Antimicrobial susceptibility testing",
        "Minimal inhibitory concentration (MIC) determination"
    ],
    "Submission Type(s)": [
        "System",
        "Panel",
        "Reagent",
        "Instrument",
        "Software",
        "Broth"
    ],
    "Document Summary": "FDA 510(k) summary for BD Phoenix Automated Microbiology System Cefazolin panel for rapid identification and antimicrobial susceptibility testing using broth microdilution and automated analysis.",
    "Indications for Use Summary": "Intended for in vitro quantitative determination of antimicrobial susceptibility by MIC of Gram-negative and Gram-positive bacterial isolates using cefazolin panels, with removal of limitations for Klebsiella oxytoca and Proteus mirabilis.",
    "fda_folder": "Microbiology"
}